Currently out of the existing stock ratings of John Newman, 153 are a BUY (86.93%), 23 are a HOLD (13.07%).

John Newman

Work Performance Price Targets & Ratings Chart

Analyst John Newman, currently employed at CANACCORD, carries an average stock price target met ratio of 38.29% that have a potential upside of 21.75% achieved within 118 days.

John Newman’s has documented 300 price targets and ratings displayed on 32 stocks. The coverage is on Healthcare, Financial Services sectors.

Most recent stock forecast was given on REGN, Regeneron Pharmaceuticals at 13-Oct-2025.

Wall Street Analyst John Newman

Analyst best performing recommendations are on APTO (APTOSE BIOSCIENCES).
The best stock recommendation documented was for ACLX (ARCELLX) at 4/19/2023. The price target of $40 was fulfilled within 5 days with a profit of $4.74 (13.44%) receiving and performance score of 26.89.

Average potential price target upside

of $438.02 (23.79%) on BLUE (BLUEBIRD BIO).
of $221.24 (60.71%) on ATRA (ATARA BIOTHERAPEUTICS).
of $95.88 (58.38%) on APTO (APTOSE BIOSCIENCES).

AGIO Agios Pharm ATRA Atara Biotherapeutics IMGN ImmunoGen MCRB Seres Therapeutics OCUP Ocuphire Pharma REGN Regeneron Pharmaceuticals SESN Sesen Bio BLUE Bluebird bio RDUS Schnitzer Steel Industries ALDX Aldeyra The ARAV Aravive CELG Celgene GBT Global Blood Therapeutics SELB Selecta Biosciences SGYP Synergy Pharmaceuticals ACET Adicet Bio HSTO Histogen SAGE Sage Therapeutic ACLX Arcellx ALLO Allogene Therapeutics BCEL Atreca ONCY Oncolytics Biotech TSVT 2Seventy Bio BNTX BioNTech SE MRUS Merus BV APTO Aptose Biosciences ALRN Aileron Therapeutics CADL Candel Therapeutics GEMP Gemphire Therapeutics HCM HUTCHMED DRC NRBO Neurobo Pharmaceuticals TIG Trean Insurance Group

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Emily Bodnar (HC WAINWRIGHT)